SEC For					TEC									SSION				
FORM 4 UNITED STA					TES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549													
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ed purs	suant t	o Sectior	n 16(a	ES IN BI	urities E:	xchan		OMB Number: Estimated average hours per respon			verage burder	3235-0287 0 0.5	
1. Name and Address of Reporting Person <sup>*</sup> <u>Thompson Peter A.</u>									ker or Tradin apeutics,			(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) (First) (Middle) C/O SILVERBACK THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 12/03/2020								Officer (give title Other (specify below)				
500 FAIRVIEW AVENUE N, SUITE 600					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) SEATTL	(Street) SEATTLE WA 98109													X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)																		
		Tab	ole I - Nor	n-Deriv	ative	e Sec	curities	s Ac	quired, D	ispos	sed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear) i	2A. Deemed Execution Date, f any /Month/Day/Yea		Code (Ins	on Disposed C		ies Acquire Of (D) (Inst		Beneficia Owned F	s ally following	Form (D) o	r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership
						Code V			/ An	nount	ount (A) or (D) P		Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
		-							uired, Dis s, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d Date, 1	I. Fransa Code (i 3)	ction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	cisable ate		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$21	12/03/2020			Α		38,270		(1)	12/02/	/2030	Common Stock	38,270	\$0.00	38,27	0	D <sup>(2)</sup>	

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020.

2. The Reporting Person is the designated representative of OrbiMed Advisors LLC ("OrbiMed Advisors") on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

## Remarks:

## /s/ Jeffrey C. Pepe, Attorney-in-12/03/2020

Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{*}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.